Crescent Biopharma, Inc.
CBIO
$19.61
$1.156.23%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/13/2026
-
TipRanks Financial Blog
5/12/2026
-
Globe Newswire
5/12/2026
-
Tickeron - Stocks
5/7/2026
-
Simply Wall St
5/6/2026
-
MarketBeat
5/6/2026
-
Globe Newswire
5/4/2026
-
MarketBeat
5/4/2026
-
TipRanks Financial Blog
5/2/2026
-
Tickeron - Stocks
5/2/2026
-
Tickeron - Stocks
5/2/2026
-
Tickeron - Stocks
5/1/2026
-
Tickeron - Stocks
5/1/2026
-
TipRanks Financial Blog
4/30/2026
-
TipRanks Financial Blog
4/30/2026
-
Tickeron - Stocks
4/30/2026
-
Tickeron - Stocks
4/29/2026
-
Globe Newswire
4/29/2026
-
Tickeron - Stocks
4/29/2026
-
Tickeron - Stocks
4/28/2026
-
MarketBeat
4/25/2026
-
Tickeron - Technical Analysis
4/24/2026
-
Globe Newswire
4/24/2026
-
Tickeron - Stocks
4/23/2026
-
Tickeron - Technical Analysis
4/22/2026
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, February 26, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of Jul 27 and 31 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 460 5595
Address
300 Fifth Avenue
Waltham, MA 02451
Waltham, MA 02451
Country
Year Founded
Business Description
Sector
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a...
more